Palvella Therapeutics (PVLA) Interest Coverage Ratio (2014 - 2024)
Palvella Therapeutics (PVLA) reported Interest Coverage Ratio of 24.12 for Q4 2024, down 4.83% on a QoQ basis from 23.01 in Q3 2024.
Palvella Therapeutics (PVLA) has 3 years of Interest Coverage Ratio data on file, last reported at 24.12 in Q4 2024.
- Quarterly Interest Coverage Ratio changed N/A year-over-year to 24.12 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was 174.94 (down 1291.14% YoY) and the FY2024 annual result came in at 32.78, changed N/A from the prior year.
- Interest Coverage Ratio fell to 24.12 in Q4 2024 per PVLA's latest filing, from 23.01 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 23.01 in Q3 2024 and bottomed at 100.28 in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -24.12 |
| Sep 30, 2024 | -23.01 |
| Jun 30, 2024 | -100.28 |
| Jun 30, 2015 | -66,687.36 |
| Mar 31, 2015 | -887.61 |
| Jun 30, 2014 | -24.34 |
| Mar 31, 2014 | -6.14 |